is the world’s first polymer-based technology platform designed to enable cardiovascular restoration – through ETR
ETR
Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new blood vessel or heart valve.
With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.
ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.
ETR In Action
01
Xeltis devices work as normal heart valves or blood vessels once implanted.
02
New tissue forms around and inside the device to develop a new, healthy, functioning heart valve or blood vessel.
03
Xeltis devices are designed to absorb over time, leaving patients with a new, healthy, functioning heart valve or blood vessel.
RestoreX™ is the world’s first polymer-based technology designed to enable natural restoration of cardiovascular function, through a therapeutic approach called Endogenous Tissue Restoration (ETR). ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.
Product Pipeline
Pre-Clinical
Clinical
Pediatric conduit
Pulmonary Heart Valve
Aortic Heart Valve
Cardiovascular Applications
Nobel Prize-Awarded Science
Jean-Marie Lehn, Nobel Laureate.
Awarded 1987 Nobel Prize in Chemistry for pioneering supramolecular chemistry, the science at the basis of Xeltis’ technology.
“Supramolecular chemistry enables Xeltis technology by providing unique biochemical and biomechanical properties, delivering solutions to issues faced by traditional materials over the course of decades.”
Professor Lehn is a Scientific Advisor to Xeltis.
Presented Data
2018
- EACTS 2018 Techno College
One-year case study on pediatric pulmonary valve - TCT 2018 annual meeting
Long-term aortic valve in vivo trial results - ECHSA 2018 annual meeting
Preliminary 1-year clinical results on pulmonary valve - ACC 2018 annual meeting
Heart valve preclinical and clinical trial program overview
2017
- TCT 2017 annual meeting
12-month preclinical data on aortic heart valve - EuroPCR 2017 annual meeting
6-month preclinical data on aortic heart valve. - 7th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS)
Xeltis 31-month feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure
2016
- 30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting
Xeltis 2-year feasibility clinical trial data of a novel bioabsorbable vascular graft in modified Fontan procedure – mid-term results - 30th European Association for Cardio-Thoracic Surgery (EACTS) annual meeting
Xeltis 1-year in vivo data of a novel bioabsorbable pulmonary heart valved conduit - 96th American Association for Thoracic Surgery (AATS) annual meeting
Xeltis 1-year feasibility clinical trial data showed significant improvement in patients’ general conditions. - 3rd Heart Valve Society (HVS) annual meeting
Xeltis 1-year feasibility clinical trial data show significant improvement in patients’s general conditions. - 10th World Biomaterials Congress (WBC) annual meeting
Preclinical data on ETR validated potential of Xeltis technology to “guide the restoration of a patient’s natural tissue into a functional living vascular replacement.”
Academic Partnerships
Xeltis is actively involved in research collaborations with leading academic partners.
Scientific research projects enable Xeltis to increase our knowledge of ETR, by leveraging the deep scientific understanding achieved at an academic level, and to contribute to our robust knowledge of technology application in the field.
The RegMed XB Institute brings together multiple health foundations, leading scientists, entrepreneurs and government institutions to cooperatively tackle ambitious challenges in regenerative medicine.
The ImaValve Consortium, led by Professor Bouten from Eindhoven University of Technology (TU/e), aims at using intelligent materials to develop innovative solutions for the challenging research field of in situcardiovascular restoration. The ImaValve is made of a slowly degrading elastomeric polymer that can be inserted with minimally invasive surgery.
The iValve-II project is a continuation from the BMM iValve project, with a public-private consortium led by Professor Bouten from TU/e. The focus of this academic collaboration is on using restorative approaches to repair or replace damaged tissues and organs.
The InSiTeVx Consortium, led by Professor Dankers from TU/e, is investigating whether the understanding on cardiovascular restoration from previous projects can be translated to develop an off-the-shelf, synthetic, biodegradable vascular access graft for dialysis.
